The most commonly employed isotope in TARE is yttrium-90.
Yttrium-90., trim 90 is a beta particle with penetrance 2.5 mm with maximum penetrance of 11 mm.
Yttrium-90 (Y-90) Glass Microspheres (TheraSphere) are approved for the treatment of patients with hepatocellular carcinoma.
The approval is based on findings from the retrospective LEGACY trial, in which
A radiotherapeutic cancer treatment, elicited an overall response rate of 72.2% at 4 weeks per blinded independent central review (BICR) as neoadjuvant or stand-alone treatment in 143 evaluable patients with unresectable hepatocellular carcinoma. 76.1% of patients derived a duration of response of longer than 6 months with radioembolization technology.
Yttrium-90 (Y-90) Glass Microsphere (TheraSphere) is the only radioembolization technology indicated for the treatment of patients with unresectable HCC in the United States.
The LEGACY study included patients with unresectable solitary liver lesions that were 8 cm or smaller in size.
It was given as neoadjuvant therapy with the intent to bridge patients to transplant or resection or as stand-alone treatment.
LEGACY trial showed that 100% of evaluable patients derived a partial or complete response with Yttrium-90 (Y-90) Glass Microsphere per localized mRECIST criteria.
Results revealed a 3-year overall survival rate of 93% in patients who had undergone transplant or resection following treatment with Yttrium-90 (Y-90) Glass Microsphere .
Then rate of best response with Yttrium-90 (Y-90) Glass Microsphere was 88% per localized mRECIST criteria.
Almost all (93.9%) patients who received Yttrium-90 (Y-90) Glass Microsphere were alive and progression free by localized mRECIST criteria at 24 months.
The majority of adverse effects (AEs) were mild and resolved without medical intervention.
Maintained albumin and bilirubin liver function was observed in 92.9% and 85.3% of patients, respectively.
Approved for a liver brachytherapy including the treatment of colorectal cancer liver metastasis.